Overview

Absolute Bioavailability of BMS-791325

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of BMS-791325 relative to 100 µg IV infusion of [13C]-BMS-791325.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb